Vyome Holdings, Inc 8-K, filed Mar 12, 2021

Vyome Holdings, Inc (HIND)

8-K 2021-03-12 For: 2021-03-12

View Original

Added on April 07, 2026

About this 8-K

Vyome Holdings, Inc filed this 8-K on March 12, 2021.

Items reported

Item 2.02: Financial results
Item 9.01: Financial statements and exhibits

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

001- 37897		26-1828101
(Commission File Number)		(IRS Employer Identification No.)

5421 Avenida Encinas, Suite F Carlsbad, California		92008
(Address of principal executive offices)		(Zip Code)

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Exhibit Number		Description

99.1		Press Release dated March 12, 2021


	OBALON THERAPEUTICS, INC.


Date: March 12, 2021	By:	/s/ Andrew Rasdal
		Andrew Rasdal
		President and Chief Executive Officer


	Three Months Ended December 31,				Twelve Months Ended December 31,
	2020		2019		2020		2019
Revenue	$	61	$	787	$	1,588	$	3,281
Cost of revenue		(1)		627		1,004		2,950
Gross profit (deficit)		62		(160)		584		331
Operating expenses:
Research and development		157		1,492		2,450		6,893
Selling, general and administrative		1,230		3,643		8,776		16,668
Asset impairment and other charges		—		—		1,310		—
Total operating expenses		1,387		5,135		12,536		23,561
Loss from operations		(1,326)		(4,975)		(11,952)		(23,230)
Interest (expense) income, net		—		63		29		(385)
Other expense, net		—		(1)		(411)		(61)
Net loss and comprehensive loss	$	(1,326)	$	(4,913)	$	(12,334)	$	(23,676)
Net loss per share, basic and diluted	$	(0.17)	$	(0.64)	$	(1.59)	$	(5.03)
Weighted-average common shares outstanding, basic and diluted		7,770,698		7,692,673		7,738,355		4,706,775


	December 31,
	2020		2019
Assets
Current assets:
Cash and cash equivalents	$	3,905	$	14,055
Accounts receivable, net		—		285
Inventory		—		1,936
Other current assets		3,930		1,959
Total current assets		7,835		18,235
Lease right-of-use assets		521		1,077
Property and equipment, net		957		1,081
Other long-term assets		1,304		—
Total assets	$	10,617	$	20,393
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	615	$	648
Accrued compensation		65		820
Deferred revenue		—		424
Other current liabilities		3,802		1,524
Current portion of lease liabilities		564		561
Total current liabilities		5,046		3,977
Lease liabilities, long-term		438		567
Long-term debt		430		—
Other long-term liabilities		38		—
Total liabilities		5,952		4,544

Commitments and contingencies

Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized as of December 31, 2020 and December 31, 2019; 7,770,698 and 7,724,100 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively		8		8
Additional paid-in capital		189,421		188,271
Accumulated deficit		(184,764)		(172,430)
Total stockholders’ equity		4,665		15,849
Total liabilities and stockholders’ equity	$	10,617	$	20,393


	Year ended December 31,
	2020		2019
Operating activities:
Net loss	$	(12,334)	$	(23,676)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		340		479
Stock-based compensation		1,089		2,983
Fair value of cash-settled options		38		—
Issuance of warrants for the purchase of common stock		45		—
Amortization of right-of-use assets		503		415
Loss on disposal of fixed asset		—		128
Accretion of investment discount, net		—		(2)
Amortization of debt discount		—		70
Impairment of long-lived assets and other charges		1,257		—
Impairment of inventory		53		—
Change in operating assets and liabilities:
Accounts receivable, net		285		585
Inventory		(525)		12
Other current assets		(1,804)		411
Accounts payable		(33)		(543)
Accrued compensation		(740)		(2,985)
Deferred revenue		(424)		72
Lease liabilities, net		(427)		(364)
Other current and long-term liabilities		2,268		(451)
Net cash used in operating activities		(10,409)		(22,866)
Investing activities:
Maturities of short-term investments		—		2,550
Purchases of property and equipment		(171)		(194)
Net cash (used in) provided by investing activities		(171)		2,356
Financing activities:
Proceeds from issuance of common stock and warrants, net of issuance costs		—		23,377
Proceeds from long-term loan, net of issuance costs		430		10,000
Repayments of long-term loans		—		(20,000)
Proceeds from sale of common stock upon exercise of stock options		—		1
Net cash provided by financing activities		430		13,378
Net (decrease) increase in cash and cash equivalents		(10,150)		(7,132)
Cash and cash equivalents at beginning of period		14,055		21,187
Cash and cash equivalents at end of period	$	3,905	$	14,055
Supplemental cash flow information:
Interest paid	$	—	$	719
Income taxes paid	$	—	$	—
Property and equipment in accounts payable	$	—	$	32